相关实验视频

Updated: Jul 23, 2025

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

儿童瘤组2023年研究蓝图:非霍奇金淋巴瘤

Nader Kim El-Mallawany¹, Sarah Alexander², Mark Fluchel³

¹Baylor College of Medicine, Department of Pediatrics, Texas Children's Hospital, Texas Children's Cancer Center, Houston, Texas, USA.

Pediatric blood & cancer

|July 14, 2023

概括

由于合作试验,儿科非霍奇金淋巴瘤 (NHL) 的存活率大大提高,但复发/耐药病例和长期影响仍然存在挑战. 需要新的策略来为所有患有NHL和朗格汉斯细胞囊细胞瘤 (LCH) 的儿童找到最佳的治疗方法.

科学领域:

儿科瘤学儿科瘤学
血液性恶性瘤血液性恶性瘤
癌症研究癌症研究

背景情况:

儿科非霍奇金淋巴瘤 (NHL) 包含30多种组织学,每年影响约800名美国儿童.
在过去的五十年中,NHL的存活率有了显著的提高,而晚期的伯基特淋巴瘤现在的存活率超过95%.
在治疗复发性/耐药性疾病以及在NHL幸存者中管理长期发病率方面,仍然存在重大挑战.

研究的目的:

为所有被诊断患有NHL和朗格汉斯细胞细胞症 (LCH) 的儿童和年轻人确定最佳治疗方法.
为了解决对改善LCH结果的未满足需求,现在被认为是一种瘤性疾病.
推进儿童血液恶性瘤的治疗策略.

主要方法:

利用儿童瘤学合作试验模型的成功.
将兰格汉斯细胞囊细胞分裂 (LCH) 整合到NHL委员会研究组合中.
专注于改善具有挑战性的病例的生存率,包括复发和耐药性疾病.

主要成果:

儿科非霍奇金淋巴瘤 (NHL) 的整体存活率得到了显著改善.
先进的伯基特淋巴瘤现在显示的生存率超过95%.
合作试验模式在这些积极结果中发挥了重要作用.

结论:

儿科NHL和LCH的持续进展需要创新的方法.
未来的战略包括为罕见种群组建研究小组,实施基于生物学的资格标准,并探索替代终点.
国际合作和协调的相关生物学研究对进步至关重要.

关键词:

兰格拉汉斯细胞基细胞形成.临床试验临床试验临床试验临床试验临床试验非霍奇金淋巴瘤的非霍奇金淋巴瘤.儿科瘤学儿科瘤学

更多相关视频

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Modeling Chemotherapy Resistant Leukemia In Vitro

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...